UNSPSC 51422002: Sermorelin

This classification denotes a growth hormone-releasing hormone analogue with the molecular formula C149H246N44O42S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89243S03TE, chemically known as somatoliberin (human pancreatic islet), 29-l-argininamide-30-de-l-glutamine-31-de-l-glutamine-32-deglycine-33-de-l-glutamic acid-34-de-l-serine-35-de-l-asparagine-36-de-l-glutamine-37-de-l-glutamic acid-38-de-l-arginine-39-deglycine-40-de-l-alanine-41-de-l-arginine-42-de-l-alanine-43-de-l-argininyl-44-de-l-leucinamide but generally known as sermorelin, which bears US NIH Compound Identifier 16129620.

UNSPSC 51422002 Sermorelin, a Commodity code, shows minimal alignment between its nominal scope and recent state and local solicitation activity. The code's name references a specific peptide hormone used in clinical endocrinology, yet the two recent opportunities posted under it involve naloxone (an opioid-reversal medication) and a statewide pharmacy benefit program exploring direct-to-manufacturer prescription fulfillment—neither of which relates to sermorelin procurement. State and local governments appear to be using this code as a catch-all for pharmaceutical or health-services purchasing despite the code's narrow commodity definition, suggesting either tagging misclassification or a significant gap between UNSPSC taxonomy and actual procurement practice in health-services categories.

The two posted opportunities reflect different issuing bodies and procurement stages. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford; the contract includes a two-year initial term with one-year renewal option and is potentially FEMA-funded. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities and market intelligence on establishing direct-to-manufacturer prescription relationships outside traditional pharmacy benefit manager and group purchasing organization channels, signaling early-stage exploration rather than formal procurement. Recent activity concentrates in Florida and Texas, with no established pattern across additional jurisdictions. The mismatch between the code's stated commodity and the actual work being solicited suggests that firms pursuing pharmaceutical or health-services contracts under this code should verify issuing-body tagging rather than rely on UNSPSC nomenclature alone.